Literature DB >> 27439505

Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.

Gian P Camenisch1.   

Abstract

BDDCS, ECCS and ECCCS are compound disposition classification concepts that aim to streamline, de-risk and speed-up drug development. Although all three systems have the same purpose and are based on classifying drugs into four main categories, they have different backgrounds and contrast in their criteria. Here the details, differences and most important applications of the three systems are reviewed with particular emphasis of their roles for drug discovery and development.

Keywords:  BDDCS; ECCCS; ECCS; drug disposition classification; enzyme/transporter interplay

Mesh:

Substances:

Year:  2016        PMID: 27439505     DOI: 10.1007/s11095-016-2001-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

2.  The use of BDDCS in classifying the permeability of marketed drugs.

Authors:  Leslie Z Benet; Gordon L Amidon; Dirk M Barends; Hans Lennernäs; James E Polli; Vinod P Shah; Salomon A Stavchansky; Lawrence X Yu
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

3.  Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight.

Authors:  G Camenisch; J Alsenz; H van de Waterbeemd; G Folkers
Journal:  Eur J Pharm Sci       Date:  1998-10       Impact factor: 4.384

4.  The BCS, BDDCS, and regulatory guidances.

Authors:  Mei-Ling Chen; Gordon L Amidon; Leslie Z Benet; Hans Lennernas; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

5.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

6.  Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Authors:  Chelsea M Hosey; Leslie Z Benet
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

7.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

8.  Clearance mechanism assignment and total clearance prediction in human based upon in silico models.

Authors:  Franco Lombardo; R Scott Obach; Manthena V Varma; Rowan Stringer; Giuliano Berellini
Journal:  J Med Chem       Date:  2014-05-06       Impact factor: 7.446

Review 9.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

10.  Physicochemical determinants of human renal clearance.

Authors:  Manthena V S Varma; Bo Feng; R Scott Obach; Matthew D Troutman; Jonathan Chupka; Howard R Miller; Ayman El-Kattan
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

View more
  7 in total

1.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

2.  Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics.

Authors:  John F Wambaugh; Michael F Hughes; Caroline L Ring; Denise K MacMillan; Jermaine Ford; Timothy R Fennell; Sherry R Black; Rodney W Snyder; Nisha S Sipes; Barbara A Wetmore; Joost Westerhout; R Woodrow Setzer; Robert G Pearce; Jane Ellen Simmons; Russell S Thomas
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

3.  Rapid experimental measurements of physicochemical properties to inform models and testing.

Authors:  Chantel I Nicolas; Kamel Mansouri; Katherine A Phillips; Christopher M Grulke; Ann M Richard; Antony J Williams; James Rabinowitz; Kristin K Isaacs; Alice Yau; John F Wambaugh
Journal:  Sci Total Environ       Date:  2018-05-02       Impact factor: 7.963

Review 4.  IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making.

Authors:  Xiaoqing Chang; Yu-Mei Tan; David G Allen; Shannon Bell; Paul C Brown; Lauren Browning; Patricia Ceger; Jeffery Gearhart; Pertti J Hakkinen; Shruti V Kabadi; Nicole C Kleinstreuer; Annie Lumen; Joanna Matheson; Alicia Paini; Heather A Pangburn; Elijah J Petersen; Emily N Reinke; Alexandre J S Ribeiro; Nisha Sipes; Lisa M Sweeney; John F Wambaugh; Ronald Wange; Barbara A Wetmore; Moiz Mumtaz
Journal:  Toxics       Date:  2022-05-01

5.  Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.

Authors:  Arnold Donkor Forkuo; Charles Ansah; David Pearson; Werner Gertsch; Amanda Cirello; Adam Amaral; Jaimie Spear; Colin W Wright; Caroline Rynn
Journal:  BMC Pharmacol Toxicol       Date:  2017-12-22       Impact factor: 2.483

Review 6.  Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments.

Authors:  Elaine A Cohen Hubal; Barbara A Wetmore; John F Wambaugh; Hisham El-Masri; Jon R Sobus; Tina Bahadori
Journal:  J Expo Sci Environ Epidemiol       Date:  2018-08-16       Impact factor: 5.563

7.  Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.

Authors:  Felix Huth; Hilmar Schiller; Yi Jin; Birk Poller; Carole Schuhler; Wendy Weis; Ralph Woessner; Anton Drollmann; Peter End
Journal:  Clin Transl Sci       Date:  2021-08-25       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.